Novartis | NVS - Interest Expense On Debt

Stock Price
149.86
Daily Change
-1.21 -0.80%
Monthly
8.70%
Yearly
41.99%
Q1 Forecast
145.07

Novartis reported $281M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Amgen USD 685M 9M Sep/2025
AstraZeneca USD 303M 38M Jun/2025
Bausch Health Companies USD 412M 53M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Drreddys Laboratories INR 944M 127M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline GBP 167M 17M Sep/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 327M 22M Sep/2025
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 652M 2M Sep/2025
Prestige Brands USD 10.04M 167K Sep/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sanofi EUR -25M 99.78M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Zoetis USD 58M 5M Sep/2025